Daniel S. Clevenger

Partner - Boston

Bio photo for Daniel Clevenger
Download Media Photo

Contact Information



dclevenger@foleyhoag.com Download vCard

Dan Clevenger is a partner in the firm’s Business Department. Dan helps technology and life sciences companies at all stages of growth, as well as their boards, as they navigate the legal, regulatory and business hurdles companies face in the current market.

Over his 20+ year career, Dan has partnered with high-growth companies on a wide range of strategic transactions and matters, including public offerings of debt and equity securities, venture capital investments, and mergers and acquisitions. In addition to his transactional work, Dan also has extensive experience advising public companies on compliance with United States federal securities laws, including public reporting, proxy solicitations and shareholder communications.

More »


  • College of William and Mary, J.D., 1999
  • Virginia Tech, B.S. in Biochemistry, 1996

Representative Experience

  • Represented Novellus Therapeutics, a developer of novel medicines intended for the treatment of pediatric disease, in its sale to Brooklyn ImmunoTherapeutics (NYSE: BTX) for $125 million 
  • Represented computer-aided engineering company Exa Corporation (Nasdaq :EXA) in its $400M sale to French software company Dassault. 
  • Represented Living Proof, Inc. in its acquisition by Unilever.
  • Represented Applied Genetic Technologies Corporation, a Florida-based biotechnology company, in its initial public offering and subsequent follow-on offering.
  • Represented Hittite Corporation in its sale to Analog Devices, Inc.
  • Represented lead investor in $75 million Series B financing of a pharmaceuticals company.
  • Represented a healthcare information management company and its equity holders in $68.5 million sale to a strategic buyer.
  • Represented Exa Corporation, a Massachusetts-based provider of software simulation tools, in its initial public offering.
  • Represented Art Technology Group, a provider of e-commerce software, in its $1.0 billion sale to Oracle Corporation.
  • Represented lead investor in $55 million investment in development stage biopharmaceutical company.
  • Represented Alere Inc., NYSE-listed medical device manufacturer, in private and public offerings of debt securities with an aggregate principal amount of $1.05 billion.
Add to Bio Folder

Download Bio

Bar Admissions

  • Massachusetts
  • Virginia